IDEAS home Printed from https://ideas.repec.org/a/wly/riskan/v24y2004i6p1683-1687.html
   My bibliography  Save this article

Role of the Standard Deviation in the Estimation of Benchmark Doses with Continuous Data

Author

Listed:
  • David W. Gaylor
  • William Slikker

Abstract

For continuous data, risk is defined here as the proportion of animals with values above a large percentile, e.g., the 99th percentile or below the 1st percentile, for the distribution of values among control animals. It is known that reducing the standard deviation of measurements through improved experimental techniques will result in less stringent (higher) doses for the lower confidence limit on the benchmark dose that is estimated to produce a specified risk of animals with abnormal levels for a biological effect. Thus, a somewhat larger (less stringent) lower confidence limit is obtained that may be used as a point of departure for low‐dose risk assessment. It is shown in this article that it is important for the benchmark dose to be based primarily on the standard deviation among animals, sa, apart from the standard deviation of measurement errors, sm, within animals. If the benchmark dose is incorrectly based on the overall standard deviation among average values for animals, which includes measurement error variation, the benchmark dose will be overestimated and the risk will be underestimated. The bias increases as sm increases relative to sa. The bias is relatively small if sm is less than one‐third of sa, a condition achieved in most experimental designs.

Suggested Citation

  • David W. Gaylor & William Slikker, 2004. "Role of the Standard Deviation in the Estimation of Benchmark Doses with Continuous Data," Risk Analysis, John Wiley & Sons, vol. 24(6), pages 1683-1687, December.
  • Handle: RePEc:wly:riskan:v:24:y:2004:i:6:p:1683-1687
    DOI: 10.1111/j.0272-4332.2004.559_1.x
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/j.0272-4332.2004.559_1.x
    Download Restriction: no

    File URL: https://libkey.io/10.1111/j.0272-4332.2004.559_1.x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Kenny S. Crump, 1995. "Calculation of Benchmark Doses from Continuous Data," Risk Analysis, John Wiley & Sons, vol. 15(1), pages 79-89, February.
    2. David W. Gaylor & William Slikker, 1994. "Modeling for Risk Assessment of Neurotoxic Effects," Risk Analysis, John Wiley & Sons, vol. 14(3), pages 333-338, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Susan Dekkers & Jan Telman & Monique A. J. Rennen & Marco J. Appel & Cees De Heer, 2006. "Within‐Animal Variation as an Indication of the Minimal Magnitude of the Critical Effect Size for Continuous Toxicological Parameters Applicable in the Benchmark Dose Approach," Risk Analysis, John Wiley & Sons, vol. 26(4), pages 867-880, August.
    2. Signe M. Jensen & Felix M. Kluxen & Christian Ritz, 2019. "A Review of Recent Advances in Benchmark Dose Methodology," Risk Analysis, John Wiley & Sons, vol. 39(10), pages 2295-2315, October.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Katsuyuki Murata & Esben Budtz‐Jørgensen & Philippe Grandjean, 2002. "Benchmark Dose Calculations for Methylmercury‐Associated Delays on Evoked Potential Latencies in Two Cohorts of Children," Risk Analysis, John Wiley & Sons, vol. 22(3), pages 465-474, June.
    2. Zi-Fan Yu & Paul J. Catalano, 2005. "Quantitative Risk Assessment for Multivariate Continuous Outcomes with Application to Neurotoxicology: The Bivariate Case," Biometrics, The International Biometric Society, vol. 61(3), pages 757-766, September.
    3. Walter W. Piegorsch, 2010. "Translational benchmark risk analysis," Journal of Risk Research, Taylor & Francis Journals, vol. 13(5), pages 653-667, July.
    4. Kenny S. Grump & Tord Kjellström & Annette M. Shipp & Abraham Silvers & Alistair Stewart, 1998. "Influence of Prenatal Mercury Exposure Upon Scholastic and Psychologica Test Performance: Benchmark Analysis of a New Zealand Cohort," Risk Analysis, John Wiley & Sons, vol. 18(6), pages 701-713, December.
    5. Maria A. Sans‐Fuentes & Walter W. Piegorsch, 2021. "Benchmark dose risk analysis with mixed‐factor quantal data in environmental risk assessment," Environmetrics, John Wiley & Sons, Ltd., vol. 32(5), August.
    6. Walter W. Piegorsch & Hui Xiong & Rabi N. Bhattacharya & Lizhen Lin, 2014. "Benchmark Dose Analysis via Nonparametric Regression Modeling," Risk Analysis, John Wiley & Sons, vol. 34(1), pages 135-151, January.
    7. Kristi Kuljus & Dietrich Von Rosen & Salomon Sand & Katarina Victorin, 2006. "Comparing Experimental Designs for Benchmark Dose Calculations for Continuous Endpoints," Risk Analysis, John Wiley & Sons, vol. 26(4), pages 1031-1043, August.
    8. Mirjana Glisovic‐Bensa & Walter W. Piegorsch & Edward J. Bedrick, 2024. "Bayesian benchmark dose risk assessment with mixed‐factor quantal data," Environmetrics, John Wiley & Sons, Ltd., vol. 35(5), August.
    9. Steven B. Kim & Ralph L. Kodell & Hojin Moon, 2014. "A Diversity Index for Model Space Selection in the Estimation of Benchmark and Infectious Doses via Model Averaging," Risk Analysis, John Wiley & Sons, vol. 34(3), pages 453-464, March.
    10. Walter W. Piegorsch & R. Webster West, 2005. "Benchmark Analysis: Shopping with Proper Confidence," Risk Analysis, John Wiley & Sons, vol. 25(4), pages 913-920, August.
    11. Matthew W. Wheeler & A. John Bailer & Tarah Cole & Robert M. Park & Kan Shao, 2017. "Bayesian Quantile Impairment Threshold Benchmark Dose Estimation for Continuous Endpoints," Risk Analysis, John Wiley & Sons, vol. 37(11), pages 2107-2118, November.
    12. Signe M. Jensen & Felix M. Kluxen & Christian Ritz, 2019. "A Review of Recent Advances in Benchmark Dose Methodology," Risk Analysis, John Wiley & Sons, vol. 39(10), pages 2295-2315, October.
    13. Mirjam Moerbeek & Aldert H. Piersma & Wout Slob, 2004. "A Comparison of Three Methods for Calculating Confidence Intervals for the Benchmark Dose," Risk Analysis, John Wiley & Sons, vol. 24(1), pages 31-40, February.
    14. Matteo Goldoni & Maria Vittoria Vettori & Rossella Alinovi & Andrea Caglieri & Sandra Ceccatelli & Antonio Mutti, 2003. "Models of Neurotoxicity: Extrapolation of Benchmark Doses in Vitro," Risk Analysis, John Wiley & Sons, vol. 23(3), pages 505-514, June.
    15. Hoda Izadi & Jean E. Grundy & Ranjan Bose, 2012. "Evaluation of the Benchmark Dose for Point of Departure Determination for a Variety of Chemical Classes in Applied Regulatory Settings," Risk Analysis, John Wiley & Sons, vol. 32(5), pages 830-835, May.
    16. Keiko Kubo & Kazuhiro Nogawa & Teruhiko Kido & Muneko Nishijo & Hideaki Nakagawa & Yasushi Suwazono, 2017. "Estimation of Benchmark Dose of Lifetime Cadmium Intake for Adverse Renal Effects Using Hybrid Approach in Inhabitants of an Environmentally Exposed River Basin in Japan," Risk Analysis, John Wiley & Sons, vol. 37(1), pages 20-26, January.
    17. Harvey J. Clewell & Gregory A. Lawrence & Donald B. Calne & Kenny S. Crump, 2003. "Determination of an Occupational Exposure Guideline for Manganese Using the Benchmark Method," Risk Analysis, John Wiley & Sons, vol. 23(5), pages 1031-1046, October.
    18. Chu‐Chih Chen & James J. Chen, 2014. "Benchmark Dose Calculation for Ordered Categorical Responses," Risk Analysis, John Wiley & Sons, vol. 34(8), pages 1435-1447, August.
    19. Jingyu Liu & Walter W. Piegorsch & A. Grant Schissler & Susan L. Cutter, 2018. "Autologistic models for benchmark risk or vulnerability assessment of urban terrorism outcomes," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 181(3), pages 803-823, June.
    20. Esben Budtz-Jørgensen & Niels Keiding & Philippe Grandjean, 2001. "Benchmark Dose Calculation from Epidemiological Data," Biometrics, The International Biometric Society, vol. 57(3), pages 698-706, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:riskan:v:24:y:2004:i:6:p:1683-1687. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://doi.org/10.1111/(ISSN)1539-6924 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.